Topical cyclosporine A in the prevention of pterygium recurrence

Ophthalmologica

Volumn 222, Issue 6, 2008, Pages 391-396

  Yalcin Tok, Ozlem ^a,c   Burcu Nurozler, Ayse ^a   Ergun, Gul ^b   Akbas Kocaoglu, Fatma ^a   Duman, Sunay ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

^c NONE   (Turkey)

Author keywords

Pterygium; Pterygium recurrence; Restasis ; Topical cyclosporine A

Indexed keywords

CYCLOSPORIN A; EYE DROPS;

ADULT; AGE; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HUMAN; POSTOPERATIVE CARE; PTERYGIUM; RECURRENCE RISK;

ADMINISTRATION, TOPICAL; AGED; AGED, 80 AND OVER; CYCLOSPORINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; OPHTHALMOLOGIC SURGICAL PROCEDURES; PTERYGIUM; RECURRENCE; RETROSPECTIVE STUDIES; TURKEY;

EID: 50549089061     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000151740     Document Type: Article

References (54)

1. Caliskan S, Orhan M, Irkec M: Intraoperative mitomycin C for pterygium surgery. Ophthalmology 1999;106:208-209.
2. Luanratanakorn P, Ratanapakorn T, Suwan-Apichon O, Chuck RS: Randomized controlled study of conjunctival autograft versus amniotic membrane graft in pterygium excision. Br J Ophthalmol 2006;90:1476-1480.
3. Duke-Elder S: System of Ophthalmology: Disease of the Outer Eye. St Louis, Mosby, 1965, vol VIII, pp 573-583.
4. Cameron ME: Pterygium throughout the World. Springfield, Thomas, 1965, pp 1-4.
5. Dushku N, Reid TW: Immunohistochemical evidence that human pterygia originate from an invasion of vimentin-expressing altered limbal epithelial basal cells. Curr Eye Res 1994;13:473-481.
6. Hill JC, Maske R: Pathogenesis of pterygium. Eye 1989;3:218-226.
7. Thoft RA, Wiley LA, Sundarraj N: The multipotential cells of the limbus. Eye 1989;3:109-113.
8. Akarsu C, Taner P, Ergin A: 5-Fluorouracil as chemo adjuvant for primary pterygium surgery: preliminary report. Cornea 2003;22:522-526.
9. Pico G: Surgery for pterygium; in Smith BC, Della Rocca RC, Nesi FA, et al (eds): Ophthalmic Plastic and Reconstructive Surgery. St Louis, Mosby, 1987, pp 1416-1424.
10. Small RG: Pterygium;in Hornblass A (ed): Oculoplastic, Orbital and Reconstructive Surgery. Baltimore, Williams & Wilkins, 1988, pp 692-703.
11. Jaros PA, DeLuise VP: Pingueculae and pterygia. Surv Ophthalmol 1988;33:41-49.
12. Sebban A, Hirst LW: Pterygium recurrence rate at the Princess Alexandra Hospital. Aust NZ J Ophthalmol 1991;19:203-206.
13. Kenyon KR, Wagoner MD, Hettinger ME: Conjunctival autograft transplantation for advanced and recurrent pterygium. Ophthalmology 1985;92:1461-1470.
14. Zauberman H: Pterygium and its recurrence. Am J Ophthalmol 1967;63:1780-1786.
15. Bekibele CO, Baiyeroju AM, Ajayi BG: 5-fluorouracil vs. beta-irradiation in the prevention of pterygium recurrence. Int J Clin Pract 2004;58:920-923.
16. Kleis W, Pico G: Thio-tepa therapy to prevent postoperative pterygium occurrence and neovascularization. Am J Ophthalmol 1973;76:371-373.
17. Oguz H, Basar E, Gurler B: Intraoperative application versus postoperative mitomycin C eye drops in pterygium surgery. Acta Ophthalmol Scand 1999;77:147-150.
18. Apayd?n KC, Duranoglu Y, Saka O, et al: Argon laser treatment of pterygium. Ann Ophthalmol 2002;34:26-29.
19. Fernandes M, Sangwan VS, Bansal AK, Gangopadhyay N, Sridhar MS, Garg P, Aasuri MK, Nutheti R, Rao GN: Outcome of pterygium surgery: analysis over 14 years. Eye 2005;19:1182-1190.
20. Talu H, Tasindi E, Ciftci F, Yildiz TF: Excimer laser phototherapeutic keratectomy for recurrent pterygium. J Cataract Refract Surg 1998;24:1326-1332.
21. Koo J, Lee J: Cyclosporine: what clinicians need to know. Dermatol Clin 1995;13:897-907.
22. Secchi AG, Tognon MS, Leonardi A: Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis. Am J Ophthalmol 1990;110:641-645.
23. Zhao JC, Jin XY: Local therapy of corneal allograft rejection with cyclosporine. Am J Ophthalmol 1995;119:189-194.
24. Zhao JC, Jin XY: Immunological analysis and treatment of Mooren's ulcer with cyclosporin A applied topically. Cornea 1993;12:481-488.
25. Gunduz K, Ozdemir O: Topical cyclosporin as an adjunct to topical acyclovir treatment in herpetic stromal keratitis. Ophthalmic Res 1997;29:405-408.
26. Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder SC: A unified theory of the role of the ocular surface in dry eye. Adv Exp Med Biol 1998;438:643-651.
27. Borel JF, Baumann G, Chapman I, Donatsch P, Fahr A, Mueller EA, Vigouret JM: In vivo pharmacological effects of ciclosporin and some analogues. Adv Pharmacol 1996;35:115-246.
28. Insler MS, Caldwell DR: Peripheral disease (Terrien's and recurrent pterygium); in Brightbill FS (ed): Corneal Surgery: Theory, Technique, and Tissue. St Louis, Mosby, 1986, pp 387-395.
29. Singh G, Wilson MR, Foster CS: Mitomycin eye drops as treatment for pterygium. Ophthalmology 1988;95:813-821.
30. Chen PP, Ariyasu RG, Kaza V, LaBree LD, McDonnell PJ: A randomized trial comparing mitomycin C and conjunctival autograft after excision of primary pterygium. Am J Ophthalmol 1995;120:151-160.
31. Lam DS, Wong AK, Fan DS, Chew S, Kwok PS, Tso MO: Intraoperative mitomycin C to prevent recurrence of pterygium after excision: a 30-month follow-up study. Ophthalmology 1998;105:901-904.
32. Bahrassa F, Datta R: Postoperative beta radiation treatment of pterygium. Int J Radiat Oncol Biol Phys 1983;9:679-684.
33. Rao SK, Lekha T, Mukesh BN, Sitalakshmi G, Padmanabhan P: Conjunctival-limbal autografts for primary and recurrent pterygia: technique and results. Indian J Ophthalmol 1998;46:203-209.
34. Sebban A, Hirst LW: Treatment of pterygia in Queensland. Aust NZ J Ophthalmol 1991;19:123-127.
35. Brenner DJ, Merriam GR Jr: Postoperative irradiation for pterygium: guidelines for optimal treatment. Int J Radiat Oncol Biol Phys 1994;30:721-725.
36. Tarr KH, Constable IJ: Late complications of pterygium treatment. Br J Ophthalmol 1980;64:496-505.
37. Moriarty AP, Crawford GJ, McAllister IL, Constable IJ: Severe corneoscleral infection: a complication of beta irradiation scleral necrosis following pterygium excision. Arch Ophthalmol 1993;111:947-951.
38. Fisher JF, Aristoff PA: The chemistry of DNA modification by antitumor antibiotics. Prog Drug Res 1988;32:411-498.
39. Pikkel JAU, Porges YAU, Oshika A: Halting pterygium recurrence by postoperative 5-fluorouracil. Cornea 2001;20:168-171.
40. Hayasaka S, Noda S, Yamamoto Y, Setogawa T: Postoperative instillation of low-dose mitomycin C in the treatment of primary pterygium. Am J Ophthalmol 1988;106:715-718.
41. Frucht-Pery J, Ilsar M: The use of low-dose mitomycin C for prevention of recurrent pterygium. Ophthalmology 1994;101:759-762.
42. Dunn JP, Seamone CD, Ostler HB, Nickel BL, Beallo A: Development of scleral ulceration and calcification after pterygium excision and mitomycin therapy. Am J Ophthalmol 1991;112:343-344.
43. Rubinfeld RS, Pfister RR, Stein RM, Foster CS, Martin NF, Stoleru S, Talley AR, Speaker MG: Serious complications of topical mitomycin-C after pterygium surgery. Ophthalmology 1992;99:1647-1654.
44. Baudouin C, Fredj-Reygrobellet D, Gastaud P, Lapalus P: HLA DR and DQ distribution in normal human ocular structures. Curr Eye Res 1988;7:903-911.
45. Vorkauf M, Duncker G, Nolle B, Sterry W: Adhesion molecules in normal human conjunctiva: an immunohistological study using monoclonal antibodies. Graefes Arch Clin Exp Ophthalmol 1993;231:323-330.
46. Ratnakar KS, Goswamy V, Agarwal LP: Mast cells and pterygium. Acta Ophthalmol (Copenh) 1976;54:363-368.
47. Powers MR, Qu Z, O'Brien B, Wilson DJ, Thompson JE, Rosenbaum JT: Immunolocalization of bFGF in pterygia: association with mast cells. Cornea 1997;16:545-549.
48. Matsuda S, Koyasu S: Mechanisms of action of cyclosporine. Immunopharmacology 2000;47:119-125.
49. Power WJ, Mullaney P, Farrell M, Collum LM: Effect of topical cyclosporin A on conjunctival T cells in patients with secondary Sjögren's syndrome. Cornea 1993;12:507-511.
50. Kunert KS, Tisdale AS, Stern ME, Smith JA, Gipson IK: Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol 2000;118:1489-1496.
51. Oran A, Marshall JS, Kondo S, Paglia D, McKenzie RC. Cyclosporin inhibits intercellular adhesion molecule-1 expression and reduces mast cell numbers in the asebia mouse model of chronic skin inflammation. Br J Dermatol 1997;136:519-526.
52. Bleik JH, Tabbara KF: Topical cyclosporine in vernal keratoconjunctivitis. Ophthalmology 1991;98:1679-1684.
53. Stevenson D, Tauber J, Reis BL: Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology 2000;107:967-974.
54. Pucci N, Novembre E, Cianferoni A, Lombardi E, Bernardini R, Caputo R, Campa L, Vierucci A: Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. Ann Allergy Asthma Immunol 2002;89:298-303.